indicated that an immunosuppressive subtype of tumor featured high immune infiltration, stromal enrichment, and TGF-β signaling pathway activation, which is likely suitable for anti-PD-L1 and anti-TGF-β combined therapy (84). This evidence concerns the gene CD274 and neoplasm.